UNSPSC 51332509: Fluanisone

This classification denotes an antipsychotic agent with the molecular formula C21H25FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1D0W98U1I4, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(2-methoxyphenyl)-1-piperazinyl)- (9ci) but generally known as fluanisone, which bears US NIH Compound Identifier 15139. European Medicines Agency schedules Fluanisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07662MIG.

UNSPSC 51332509 Fluanisone is a Commodity code that nominally names a specific pharmaceutical compound, but recent state and local activity shows no solicitations actually purchasing fluanisone itself. Instead, the code is being applied to three substantively different pharmaceutical and health-services procurements: naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. The mismatch suggests either broad mistagging in state and local procurement systems or that the code is being used as a catch-all for miscellaneous pharmaceutical purchases outside narrower commodity classifications. The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances, indicating the code sees activity across diverse government tiers and geographic scales.

Recent opportunities include Seminole County, Florida's competitive bid (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas Health and Human Services Commission's exploratory RFI (HHS0017013, April 3, 2026) on direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers across participating state and local government facilities in Minnesota and Oregon. Activity clusters in the Southeast (Florida) and Upper Midwest (Minnesota, with Oregon participation), with Texas exploring emerging pharmacy contracting models. The code shows little relevant recent activity aligned with its nominal scope and should be treated as a low-priority watch unless your firm supplies naloxone, OTC pharmaceuticals, or related drug deactivation systems to state and local health departments.